A ustralian doctors have been spoilt for choice by the recent availability of 3 new blood pressure guidelines from the Australian National Heart Foundation (NHF), 1 the American College of Cardiology/American Heart Association (ACC/AHA), 2 and most recently the European Society of Cardiology/European Society of Hypertension (ESC/ESH). 3 However, they have also been confronted by difficult choices because these guidelines do not agree on some fundamentals.
In this brief review, using the previous 2010 NHF guidelines as a reference, we examine the potential clinical and financial impacts of the new NHF and ACC/AHA guidelines for Australians generally and in the growing elderly population. The issue of aging deserves attention because blood pressure and the incidence of hypertension rises with age 4 and the number of elderly is steadily increasing. 5 Blood pressure and its complications are important financially. In Australia, out of an annual total government health expenditure of $115 billion, 6 cardiovascular disease (CVD) accounts for ≈12%, almost one quarter of which is spent on hypertension 7 with the majority of these costs in the older population.
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Guideline Evolution
Clinical trials are the lifeblood of guidelines, but the translation of research data into practical advice involves opinion as well as science. Notwithstanding, safer and more effective drugs have seen thresholds and targets for treatment fall. Until recently, this fall has been less steep in the elderly, 8 probably reflecting the impression that high blood pressure is just part of growing old and that the elderly are often frail and susceptible to side effects of antihypertensive medications and partly because they have been relatively underrepresented in clinical trials.
Guidelines Pre-SPRINT
A series of placebo-controlled trials including Sys-Eur (Systolic Hypertension in Europe), SHEP (Systolic Hypertension in the Elderly Program), and HYVET (Hypertension in the Very Elderly Trial) subject to a Cochrane Review 9 demonstrated the benefits of treating high blood pressure in the elderly. Guidelines in the few years before 2016, such as those from the Australian NHF, 10 American Society of Hypertension/International Society of Hypertension, 11 the ESC/ESH, 12 and Eighth Joint National Committee 13 were generally recommending higher treatment targets for blood pressure in the elderly (typically 150 mm Hg systolic) than in the young (<140 mm Hg systolic).
Guidelines Post-SPRINT
The publication of SPRINT (Systolic Blood Pressure Intervention Trial) in 2015 14 challenged the status quo. In particular, the SPRINT subgroup analysis in the elderly of 75 years or more 15 (SPRINT Senior) showed benefit in aiming for a target of <120 mm Hg systolic, up to 30 mm Hg below prevailing recommendations.
The recent NHF, 1 ACC/AHA, 2 and ESC/ESH 3 guidelines produced since the publication of SPRINT seem no closer to an accord, in part reflecting the debate regarding the SPRINT population and the means of blood pressure measurement.
SPRINT Versus the Real World
SPRINT was quite selective and did not include many important groups, some of particular relevance to the elderly. For example, excluded were those with type-2 diabetes mellitus, past stroke, dementia, heart failure, and expected survival <3 years. 15 Type-2 diabetes mellitus alone is reported in 17% of Australians aged 75 years or more. 4 More problematic was the fact that SPRINT used systolic pressures that were measured as the mean of 3 automated cuff readings, after 5 minutes of quiet rest without staff in the room. 15 Such unattended measures typically record blood pressures 5 to 15 mm Hg lower than the standard clinic measurements 16 on which clinical decisions and guideline recommendations are primarily based.
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Australian Guidelines
The 2016 NHF guidelines recommend the initiation of drug treatment in patients with low-CVD risk (<10%; 5-year risk) and a clinic systolic pressure of ≥160 mm Hg. For those at moderate (10%-15%; 5-year risk) CVD risk, the treatment threshold is 140 mm Hg systolic. The guidelines recommended that all those requiring antihypertensive treatment should be treated to a primary target of <140 mm Hg systolic, including those with a history of chronic kidney disease, peripheral vascular disease, stroke, and diabetes mellitus. However, in selected high (>15%; 5-year risk) CVD risk populations including those diabetic subjects in whom stroke prevention is prioritized and those with chronic kidney disease, a secondary target of <120 mm Hg systolic can be considered. 1 For elderly individuals of ≥75 years, no specific threshold
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for commencing treatment is provided, but the primary recommended systolic target is <120 mm Hg, 1 some 20 mm Hg lower than the primary targets for the younger population.
The NHF guidelines recognized that SPRINT pressures would be lower than clinic readings, but their recommendations appeared not to convert accordingly. A clinic target <120 mm Hg is likely equivalent to a SPRINT pressure of <110 mm Hg. Present evidence does not support such a target. Indeed, SPRINT excluded patients with standing pressures <110 mm Hg to avoid complications of postural hypotension-a common problem in the elderly. 17 Notwithstanding, the Australian guidelines stressed that their clinic target of <120 mm Hg should be pursued where well-tolerated and with close follow-up.
American Guidelines
The 2017 ACC/AHA guidelines recommended a clinic systolic pressure target of <130 mm Hg for uncomplicated hypertension (unless with low-CVD risk, where the target was ≤140 mm Hg) and for noninstitutionalized, ambulatory, community-dwelling adults aged 65 years or more. 2 This clinic pressure might equate to a SPRINT pressure of <120 mm Hg, although this was not an explicit justification for the target.
European Guidelines
The ESC/ESH guidelines 3 taskforce found SPRINT difficult to interpret because blood pressure was measured differently from virtually all other randomized trials. Nevertheless, the European guidelines recommend a clinic systolic pressure target of <130 mm Hg for uncomplicated hypertension in adults up to 65 years of age. For adults aged 65 to 80 years, the threshold for treatment is a systolic pressure of 140 mm Hg. For those >80 years, the threshold is 160 mm Hg, but if treatment is tolerated the target is <140 mm Hg in all adults of 65 years or older.
Diastolic Pressure
SPRINT focused on systolic pressure, yet diastolic pressure is important for oxygen and nutrient delivery to the myocardium. After 60 years of age diastolic pressures tend to fall. 4 For a systolic pressure of <120 mm Hg, SPRINT Senior would suggest 15 that a clinic diastolic pressure of <60 mm Hg might result. If these diastolic levels are achieved as routine clinic measures, their safety and coronary effects are unknown. Guidelines such as the ESC/ESH recommend that clinic diastolic pressure should be no lower than 70 mm Hg. 
Diabetes Mellitus
Hypertension is common in diabetic subjects who were excluded from SPRINT, but the effects of intensive pressure reduction in diabetes mellitus in the ACCORD trial (Action to Control Cardiovascular Risk in Diabetes) were generally consistent with SPRINT. 18 For middle-aged diabetics, the American and European guidelines target systolic pressures of <130 mm Hg, whereas the Australian guidelines aim for <120 mm Hg. For elderly diabetic subjects, the treatment goal is <130 mm Hg in America and <140 mm Hg in Europe. The Australian target of <120 mm Hg for the elderly applies unless there is concomitant diabetes mellitus. 1 Elsewhere, the Australian guidelines recommend <140 mm Hg for diabetes mellitus, without specific reference to the elderly diabetic.
Cost Implications of the New Guidelines for Australia
Using a baseline of the pre-2016 Australian NHF guidelines, we examined the effects in the Australian population 4 of applying systolic pressure thresholds for antihypertensive treatment from the new ACC/AHA and the new NHF guidelines. We consider separately those aged 25 to 74 years and those of ≥75 years. In the younger group, we used estimates of the proportions of low, moderate/high CVD risks to calculate the number of individuals that would fall into the various systolic blood pressure/risk groups. 19 We assumed reasonable equivalence between the low (<10%) CVD risk as defined in the NHF (over 5 years) and ACC/AHA (over 10 years) guidelines.
For the Australian adult population as a whole, 2.2 million more people would be considered newly eligible for antihypertensive treatment under the ACC/AHA guidelines, compared with 0.7 million under the new NHF guidelines (Table) . The difference reflects ≈1.5 million low-CVD risk individuals aged 25 to 74 years newly eligible under the ACC/AHA guidelines. However, for individuals ≥75 years, fewer would be newly eligible under the ACC/AHA guidelines (213 300) than under the new NHF guidelines (456 700) as a result of the lower new NHF target of <120 mm Hg (Table) .
We examined the potential costs of clinical management and drug treatment and the savings that might accrue from improved blood pressure and reduced CVD risk. We assumed that 50% of subjects would take prescribed treatments and reach targets with on average a combination of 2 different classes of antihypertensive drugs. We have not modeled the ineligibility of elderly subjects because of frailty or institutionalization that might lower costs or the effects of increasing therapy in existing treated hypertensive subjects that might increase costs.
Overall (all ages, government+patient out-of-pocket), the ACC/AHA guidelines would come at a higher net annual cost of $965.7 million compared with $263.4 million for the new NHF guidelines (Table) .
The greatest impact of the ACC/AHA guidelines would be in the 25 to 74 years age group ($892 million annually; Table) . The government bears the majority of these costs (Table) , but patients contribute substantial annual out-of-pocket costs for medications amounting to $486.3 million under the ACC/ AHA guidelines and $57.3 million for Australian guidelines.
The cost differential between guidelines is reversed in the elderly with just over twice the number of newly eligible patients for the new NHF guidelines compared with the ACC/AHA recommendations (Table) . The government and patient expenses show the same differential (Table) . In this context, it is worth noting that the number of elderly Australians eligible for antihypertensive treatment and their associated costs will double by 2030.
Conclusions
High profile clinical trials such as SPRINT rekindle interest in blood pressure with the general benefit of improving diagnosis, treatment, and control of hypertension. Yet in translating SPRINT data, guidelines are more divided than united, leaving ultimate choices to clinicians. Those physicians who favor greater intervention may opt for the ACC/AHA recommendations for patients <75 years and for the new NHF guidelines for those ≥75 years. More conservative physicians might choose the reverse combination. The resulting practice treatment profiles would be dramatically different. It seems that consensus is not a term that one can readily apply to blood pressure guidelines and as a result, physicians managing patients with hypertension and associated disorders face many difficult choices. 
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